)
GlaxoSmithKline Pharmaceuticals (500660) investor relations material
GlaxoSmithKline Pharmaceuticals Q2 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Celebrated 101 years in India, entering the 102nd year with a focus on general medicines, vaccines, specialty, and a renewed push into oncology with new product launches in Q2.
Specialty and vaccine businesses delivered strong double-digit growth, with new oncology assets launched and early revenue contribution already visible.
Portfolio transformation and digital engagement strategies are driving market competitiveness, reaching ~400,000 HCPs and 5 million touchpoints.
Leadership team with extensive experience in pharmaceuticals and regional markets.
Unaudited consolidated financial results for Q2 and H1 FY2025-26 were approved, with auditors confirming compliance and no material misstatements.
Financial highlights
Q2 sales/revenue were ₹974 crore (₹97,994 lakhs), a decline of 2.6% year-over-year, mainly due to supply chain disruptions and GST transition impacts.
EBITDA margin improved to 34.4%, up 250 basis points year-over-year, driven by cost savings, better product mix, and field productivity.
EPS for Q2 at ₹15.06, up 3% year-over-year.
Net profit for Q2 was ₹25,749 lakhs, up from ₹20,501 lakhs in the previous quarter and ₹25,250 lakhs in Q2 last year.
Paediatric vaccines portfolio grew 13-14% year-over-year, led by key brands.
Outlook and guidance
Double-digit growth ambition remains intact, with supply and GST issues now resolved and expected recovery in H2.
Focus remains on expanding gross margins, maintaining EBITDA margins, and accelerating launches of innovative assets.
Specialty segment, especially oncology, expected to drive future growth, with continued focus on digital initiatives and partnerships to expand adult immunization.
Investment in renewable energy is expected to optimize energy costs and ensure compliance with captive power regulations.
No formal forward-looking guidance provided, but management is confident in growth and margin sustainability.
Next GlaxoSmithKline Pharmaceuticals earnings date
Next GlaxoSmithKline Pharmaceuticals earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage